EP0946551A2 - N-piperazin-1-ylphenyl-benzamide derives - Google Patents

N-piperazin-1-ylphenyl-benzamide derives

Info

Publication number
EP0946551A2
EP0946551A2 EP97954435A EP97954435A EP0946551A2 EP 0946551 A2 EP0946551 A2 EP 0946551A2 EP 97954435 A EP97954435 A EP 97954435A EP 97954435 A EP97954435 A EP 97954435A EP 0946551 A2 EP0946551 A2 EP 0946551A2
Authority
EP
European Patent Office
Prior art keywords
phenyl
methoxy
methylpiperazin
heterocyclic ring
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97954435A
Other languages
German (de)
English (en)
Inventor
Steven Mark Smithkline Beecham Pharm. Bromidge
Francis David Smithkline Beecham Pharm. King
Paul Adrian Smithkline Beecham Pharm. Wyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626376.9A external-priority patent/GB9626376D0/en
Priority claimed from GBGB9700902.1A external-priority patent/GB9700902D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0946551A2 publication Critical patent/EP0946551A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Definitions

  • This invention relates to compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.
  • EPA 0 021 580 and EPA 0 076 072 describe sulphonamide derivatives which are disclosed as having antiarrhythmic activity.
  • a structurally distinct class of compounds has now been discovered, which have been found to have 5HTg receptor antagonist activity.
  • 5HTg receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease (enhancement of cognitive memory), sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome).
  • the present invention therefore provides, in a first aspect, a compound of formula (I) or a salt thereof:
  • P is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;
  • A is a single bond, a C ⁇ .galkylene or a Ci .galkenylene group;
  • R.1 is halogen, C ⁇ .
  • ⁇ alkyl optionally substituted by one or more halogen atoms, C ⁇ .gcycloalkyl, COCi ⁇ alkyl, C ⁇ _6alkoxy, OCF3, hydroxy, hydroxyCi . ⁇ alkyl, 6alkylamino or diC galkylamino, cyano or Rl is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur; n is 0, 1, 2, 3, 4, 5 or 6:
  • R2 is C ⁇ _6 alkyl or aryl C ⁇ . ⁇ alkyl
  • R3 is a group R ⁇ or together with R ⁇ forms a group (CH2)2 ⁇ or (CH2)3O or R 3 is linked to R ⁇ to form a group (CH2)2 or (CH2)3;
  • R 4 is -X(CH2)p-R 6 where X is a single bond, CH , O, NH or N-C i .6alkyl and p is 0 to 6 and R ⁇ is an optionally substituted 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, sulphur or oxygen, or R ⁇ is NR ⁇ RS where R 7 and R ⁇ are independently hydrogen, C ⁇ _6 alkyl or aryl Ci _6 alkyl; and R 5 is hydrogen, halogen, C ⁇ alkyl, C3_6cycloalkyl, COC ⁇ galkyl, Ci.galkoxy, hydroxy, hydroxyC i _6alkyl, hydroxyC i _6alkoxy, C 1.galkoxyC ⁇
  • Ci .g Alkyl groups may be straight chain or branched.
  • aryl includes phenyl and naphthyl.
  • P is a bicyclic heterocyclic ring suitable examples include benzothiophene, quinoline or isoquinoline.
  • Suitable 5 to 7-membered heterocyclic rings include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl.
  • the heterocyclic rings can be linked to the remainder of the molecule via any suitable carbon atom or, when present, a nitrogen atom. Suitable substituents for these rings include R$ groups as defined above.
  • P is phenyl, thiophene, benzothiophene or naphthyl.
  • R! is a 5-7 membered heterocyclic or bicyclic heterocyclic ring suitable examples include those given within the description of group P.
  • R! is halogen or Ci .4 alkyl optionally substituted by one or more halogens, for example methyl or CF3.
  • n 0, 1, 2 or 3, particularly 1 or 2.
  • R ⁇ is C ⁇ . alkyl, in particular methyl or ethyl.
  • R ⁇ is a group R ⁇ or together with R ⁇ forms a group (CH2)2O or
  • R 3 is linked to R 2 to form a group (CH 2 )2 or (CH 2 )3.
  • R 3 is a group R$ in particular hydrogen.
  • R 4 is meta with respect to the carboxamide linkage.
  • X is a bond
  • p is 0
  • R ⁇ is an optionally substituted 5- to 7-membered heterocyclic ring.
  • the heterocyclic rings can be linked to the remainder of the molecule via a carbon atom or, when present, a nitrogen atom.
  • Optional substituents for these rings, which can be present on carbon and/or nitrogen atoms include
  • Ci .galkyl in particular methyl. More preferably R 4 is an optionally substituted piperazine. Most preferably R 4 is N-methylpiperazine or piperazine.
  • R ⁇ is Ci _6alkoxy, most preferably methoxy.
  • R$ is para with respect to the amide group.
  • Particular compounds of the invention include:
  • the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • Compounds of formula (I) may also form solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
  • the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
  • the invention also extends to any tautomeric forms and mixtures thereof.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises the coupling of a compound of formula (II):
  • R , n, P, and A are as defined in formula (I) or protected derivatives thereof and L is a leaving group with a compound of formula (III):
  • R 2 , R3, R4 and R5 ⁇ Q as defined in formula (I) or protected derivatives thereof and optionally thereafter: • removing any protecting groups, • forming a pharmaceutically acceptable salt.
  • Suitable leaving groups include halogen, in particular chloro.
  • the reaction of a compounds of formulae (II) and (III) is carried out by mixing the two reagents together, optionally in an inert solvent such as dichloromethane.
  • Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981).
  • Compounds of formula (I) and their pharmaceutically acceptable salts have 5HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease and enhancement of cognitive memory, sleep disorders (including disturbances of Circadian Rhythym), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as LBS
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.
  • the invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of the above disorders.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.
  • test compounds were dissolved in polyethylene glycol: dimethyl sulphoxide (1:1) at 1 or lOmM and diluted to O.lmM using 5mM tris buffer (pH 7.7 @ 25°C). Dissolution was assisted by addition of 0.02ml 5M HC1 plus heating to 40°C and sonication for 10 minutes. Serial dilutions of drugs in the same buffer were carried out using either a TECAN 5052 or Biomek 2000 Workstation.
  • Samples of the diluted test compounds (0.05ml) were mixed with 0.05ml of radio-ligand [ 3 H]-LSD prepared in the incubation buffer, and 0.4ml of a suspension of a preparation of the washed membranes of HeLa_5HT6 cells (acquired from Dr. D. Sibley, NIH, Bethesda, see Ref l)(see Table 1), also in the incubation buffer.
  • the details of the incubation conditions for each assay are shown in Table 2.
  • the incubation buffer was 50mM Trizma (Sigma, UK) pH7.7 @ 25°C, 4mM MgCl 2 .
  • the compounds of Examples all showed good selective 5-HT6 receptor antagonist activity, having pKi values above 7.0 at human cloned 5-HT6 receptors.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne de nouveaux dérivés de carboxamide ayant une activité sur le système nerveux central (SNC), des procédés de préparation de ces nouveaux composés ainsi que leur utilisation en tant que médicaments.
EP97954435A 1996-12-19 1997-12-15 N-piperazin-1-ylphenyl-benzamide derives Withdrawn EP0946551A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9626376 1996-12-19
GBGB9626376.9A GB9626376D0 (en) 1996-12-19 1996-12-19 Novel compounds
GB9700902 1997-01-17
GBGB9700902.1A GB9700902D0 (en) 1997-01-17 1997-01-17 Novel compounds
PCT/EP1997/007160 WO1998027058A2 (fr) 1996-12-19 1997-12-15 Nouveaux composes

Publications (1)

Publication Number Publication Date
EP0946551A2 true EP0946551A2 (fr) 1999-10-06

Family

ID=26310680

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97954435A Withdrawn EP0946551A2 (fr) 1996-12-19 1997-12-15 N-piperazin-1-ylphenyl-benzamide derives

Country Status (4)

Country Link
EP (1) EP0946551A2 (fr)
JP (1) JP2001506995A (fr)
CA (1) CA2274055A1 (fr)
WO (1) WO1998027058A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975614A1 (fr) * 1997-04-18 2000-02-02 Smithkline Beecham Plc Aryl bicyclique ou noyau heterocyclique bicyclique contenant des composes presentant une activite antagoniste combinee contre les recepteurs 5ht1a, 5ht1b et 5ht1d
PL338016A1 (en) 1997-07-11 2000-09-25 Smithkline Beecham Plc Novel chemical compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
AU758807B2 (en) * 1998-09-10 2003-03-27 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
KR20020030126A (ko) 1999-09-25 2002-04-22 피터 기딩스 ５―ｈｔ１ｂ 길항제로서의 피페라진 유도체
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
IL156595A0 (en) 2001-01-16 2004-01-04 Astrazeneca Ab Therapeutic heterocyclic compounds
JP2004517129A (ja) 2001-01-16 2004-06-10 アストラゼネカ・アクチエボラーグ 治療用クロモン化合物
GB0106586D0 (en) * 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
FR2693201B1 (fr) * 1992-07-01 1994-08-19 Inst Nat Sante Rech Med Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polyptides et utilisations.
FR2699533A1 (fr) * 1992-12-21 1994-06-24 Mouhtaram Mohamed Dérivés de N-((1,4-dialkyl-6-arylpipérazine-2-yl)méthyl)benzamides. (Isomères cis et trans) Propriétés pharmacologiques et applications.
TW240217B (fr) * 1992-12-30 1995-02-11 Glaxo Group Ltd
GB2273930A (en) * 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
PT689536E (pt) * 1993-03-16 2001-11-30 Pfizer Derivados de naftaleno
GB2276164A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
GB2276165A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide compounds.
DE69418045T2 (de) * 1993-08-06 1999-10-07 Smithkline Beecham Plc Amidderivate als 5ht1d rezeptor antagonisten
WO1995011243A1 (fr) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
EP0661266A1 (fr) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Composés cycliques aminés substitués comme 5HT2 antagonistes
EP0738144A4 (fr) * 1993-12-30 1999-06-30 Smithkline Beecham Corp Hexanamides de phenylmethyle et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9827058A2 *

Also Published As

Publication number Publication date
WO1998027058A2 (fr) 1998-06-25
CA2274055A1 (fr) 1998-06-25
WO1998027058A3 (fr) 1998-08-20
JP2001506995A (ja) 2001-05-29

Similar Documents

Publication Publication Date Title
EP0946539B1 (fr) Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
US6316450B1 (en) Compounds
US6548504B1 (en) Compounds
US7439245B2 (en) Compounds
WO1999042465A2 (fr) Nouveaux composes
US5834471A (en) Amide derivatives as 5HT1D receptor antagonists
US20050090496A1 (en) Sulphonyl compounds with 5-ht6 receptor affinity
EP0946551A2 (fr) N-piperazin-1-ylphenyl-benzamide derives
US20010051719A1 (en) Novel compounds
MXPA99005900A (en) Sulphonamide derivatives, process for their preparation, and their use as medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990429

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE ES FR GB IT LI NL

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

17Q First examination report despatched

Effective date: 20021218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040805

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023113

Country of ref document: HK